共 50 条
- [22] A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (04): : 382 - 392
- [23] Hypericum Extract WS (R) 5570 versus Paroxetine Results of a controlled, randomized, Double-blind Study in Patients with moderate to severe Depressions [J]. SCHWEIZERISCHE ZEITSCHRIFT FUER GANZHEITSMEDIZIN, 2005, 17 (06): : 336 - 337
- [24] Early response with fezolinetant treatment of moderate-to-severe vasomotor symptoms associated with menopause: pooled data from two randomized Phase 3 studies [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (12): : 1483 - 1484
- [27] Safety and efficacy of a continuous once-a-week 17β-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women:: the results of two multicenter, double-blind, randomized, controlled trials [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2002, 9 (03): : 195 - 207